Depression and Adult Hippocampal Neurogenesis - Literature Stream

1 Peng et al. 2026 — Dysregulated Adult Hippocampal Neurogenesis in MDD (PRIMARY)

(Peng et al. 2026)

Full Citation:: Peng MS, Jiang J, Polizzi L, Shi T, Ramkumar R, Anosike VO, Guasoni G, Wamalwa AM, Mariani MB, Sissoko CA, Tartt AN, Fulmore C, Rosoklija GB, Huang Y, Arango V, McDonald ST, Bitoljanu N, Mann JJ, Nguyen PT, Dwork AJ, Brown LM, Hen R, Galfalvy H, Dupont MB. Dysregulated adult hippocampal neurogenesis in major depressive disorders. Nature Medicine. 2026;32. DOI:: 10.1038/s41591-026-04571-8 Study Design:: Multimodal single-cell/post-mortem molecular atlas: single-nucleus RNA + ATAC (snMultiome), spatial transcriptomics (Visium, Xenium), regional proteomics Sample Size:: ~500,000 hippocampal nuclei; 11 nonmedicated MDD vs 19 controls (initial 14 MDD / 24 CTRL) Key Findings::

  • Identified an adult human hippocampal neurogenic lineage (NSCa, NSCb, INP, NB, ImGC) in the dentate gyrus subgranular zone, validated by fetal-hippocampus integration and spatial transcriptomics.
  • Neurogenesis is STALLED in MDD: more NSCa (quiescent stem-like), fewer neuroblasts (NBs), reduced nestin/Ki67/DCX protein — impaired progression rather than stem-cell depletion.
  • Early neurogenic stages in MDD show elevated interferon-related signaling (module 93) and heat-shock/stress genes; NBs show reduced DCX and BDNF.
  • Whole hippocampal trisynaptic circuit (DG + CA) shows disrupted excitatory-inhibitory balance, impaired synaptic plasticity and neurotransmission, cellular stress, impaired intracellular trafficking, serotonergic and glutamatergic dysfunction, and neuroinflammation.
  • Some dysregulated genes carry MDD-associated GWAS variants; others are epigenetically regulated (chromatin accessibility).
  • Pattern separation (a hippocampal function dependent on adult neurogenesis) is impaired in depression, supported by mouse ablation and radiation-ablation evidence in brain-tumor patients.
  • Findings suggest molecular reclassification of depression (analogous to cancer subtyping). Conclusion:: Provides the largest human hippocampus molecular atlas and direct evidence that adult hippocampal neurogenesis is stalled in MDD, with overlapping pathogenetic mechanisms across autoimmune, neurodevelopmental, and neurodegenerative diseases. Limitations:: Post-mortem tissue; neurogenesis in adult humans remains controversial (see Sorrells); cross-sectional; statistical significance of some DEG analyses reported at permissive thresholds (unadjusted P<0.05 with low cell numbers). Newly published (2026-08-21); not yet independently replicated. Certainty Assessment:: 0.80 raw × 1.00 direct-human-MDD weight = discounted 0.80

2 Eriksson et al. 1998 — Neurogenesis in the Adult Human Hippocampus (FOUNDATIONAL)

(Eriksson et al. 1998)

Full Citation:: Eriksson PS, Perfilieva E, Björk-Eriksson T, Alborn AM, Nordborg C, Peterson DA, Gage FH. Neurogenesis in the adult human hippocampus. Nature Medicine. 1998;4(11):1313–1317. DOI:: 10.1038/3305 PMID:: 9809557 Study Design:: Post-mortem histology of cancer patients given bromodeoxyuridine (BrdU) Key Findings::

  • BrdU-labeled cells co-expressing the mature neuronal marker NeuN were found in the dentate gyrus granule cell layer of adult human brains.
  • First direct demonstration that new neurons are generated in the adult human hippocampus. Conclusion:: Establishes the biological premise for the entire adult hippocampal neurogenesis field, including the depression-neurogenesis hypothesis and the Peng 2026 finding. Limitations:: Small number of subjects (5); cancer patients (possible treatment effects); fixed-tissue analysis. Certainty Assessment:: 0.90 raw × 1.00 direct-human weight = discounted 0.90

3 Boldrini et al. 2018 — Human Hippocampal Neurogenesis Persists Throughout Aging (COMPETING/POSITIVE)

(Boldrini et al. 2018)

Full Citation:: Boldrini M, Fulmore CA, Tartt AN, Simeon LR, Pavlova I, Poposka V, Rosoklija GB, Stankov A, Arango V, Dwork AJ, Hen R, Mann JJ. Human hippocampal neurogenesis persists throughout aging. Cell Stem Cell. 2018;22(4):589–599. DOI:: 10.1016/j.stem.2018.03.015 PMID:: 29625071 · PMCID:: PMC5957089 Study Design:: Post-mortem stereology and quantitative neurogenesis markers across the lifespan Key Findings::

  • Thousands of immature neurons are present in the adult human dentate gyrus, with ~35,000 neural stem cells per hippocampus.
  • Neurogenesis persists throughout aging into the ninth decade. Conclusion:: Directly counters the Sorrells null position, supporting that adult hippocampal neurogenesis persists at meaningful levels — the premise of the depression-neurogenesis literature. Limitations:: Post-mortem; within-field methodological disagreement with Sorrells; subject to the adult-human-neurogenesis controversy. Certainty Assessment:: 0.80 raw × 0.90 human weight = discounted 0.72

4 Boldrini et al. 2019 — Resilience, Dentate Gyrus, and Granule Neurons in MDD

(Boldrini et al. 2019)

Full Citation:: Boldrini M, Fulmore CA, Tartt AN, Simeon LR, Pavlova I, Poposka V, Rosoklija GB, Stankov A, Arango V, Dwork AJ, Hen R, Mann JJ, Galfalvy H, Haghighi F. Resilience is associated with larger dentate gyrus, while suicide decedents with major depressive disorder have fewer granule neurons. Biological Psychiatry. 2019;85(10):850–862. DOI:: 10.1016/j.biopsych.2018.12.022 PMID:: 30819514 · PMCID:: PMC6830307 Study Design:: Post-mortem stereology comparing MDD suicide decedents, non-suicide MDD, and controls Key Findings::

  • MDD suicide decedents have fewer granule neurons in the dentate gyrus.
  • Resilient individuals have a larger dentate gyrus. Conclusion:: Supports a relationship between disrupted hippocampal neurogenesis/granule-cell content and MDD severity, consistent with the Peng 2026 stalled-neurogenesis finding. Limitations:: Post-mortem; correlational; cannot prove causation; adult-neurogenesis controversy applies. Certainty Assessment:: 0.75 raw × 0.90 human-MDD weight = discounted 0.68

5 Boldrini et al. 2012 — Antidepressants Increase Hippocampal Progenitor Proliferation

(Boldrini et al. 2012)

Full Citation:: Boldrini M, Hen R, Underwood MD, Rosoklija GB, Dwork AJ, Mann JJ, Arango V. Hippocampal angiogenesis and progenitor cell proliferation are increased with antidepressant use in major depression. Biological Psychiatry. 2012;72(7):562–571. DOI:: 10.1016/j.biopsych.2012.04.024 PMID:: 22652019 · PMCID:: PMC3438317 Study Design:: Post-mortem stereology in MDD with vs without antidepressant exposure Key Findings::

  • Untreated MDD shows reduced hippocampal progenitor cell proliferation.
  • Antidepressant exposure is associated with increased progenitor cell proliferation and angiogenesis. Conclusion:: Supports the hypothesis that antidepressants restore hippocampal neurogenesis, providing the treatment-response context for the neurogenesis hypothesis. Limitations:: Post-mortem; retrospective medication history; indirect measure of neurogenesis. Certainty Assessment:: 0.70 raw × 0.85 human-MDD weight = discounted 0.60

6 Tartt et al. 2022 — Dysregulation of Adult Hippocampal Neuroplasticity in Major Depression (REVIEW)

(Tartt et al. 2022)

Full Citation:: Tartt AN, Mariani MB, Hen R, Mann JJ, Boldrini M. Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications. Molecular Psychiatry. 2022;27(6):2689–2699. DOI:: 10.1038/s41380-022-01520-y PMID:: 35354926 · PMCID:: PMC9167750 Study Design:: Review/synthesis Key Findings::

  • Synthesizes evidence that adult hippocampal neurogenesis and neuroplasticity are dysregulated in major depression.
  • Links stress, reduced neurogenesis, and hippocampal neuroplasticity deficits.
  • Reviews therapeutic implications (antidepressant and non-drug interventions). Conclusion:: Contextualizes the molecular findings of Peng 2026 within the broader neuroplasticity hypothesis of depression. Limitations:: Review; reflects the same-group interpretation; adult-neurogenesis controversy applies. Certainty Assessment:: 0.75 raw × 0.80 review weight = discounted 0.60

7 Videbech & Ravnkilde 2004 — Hippocampal Volume and Depression Meta-Analysis

(Videbech and Ravnkilde 2004)

Full Citation:: Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. American Journal of Psychiatry. 2004;161(11):1957–1966. DOI:: 10.1176/appi.ajp.161.11.1957 PMID:: 15514393 Study Design:: Meta-analysis of MRI volumetric studies Key Findings::

  • Depression is associated with reduced hippocampal volume, particularly left hippocampus in recurrent depression. Conclusion:: Provides neuroimaging-level corroboration of hippocampal dysfunction that the Peng 2026 molecular finding extends to the cellular level. Limitations:: Older (2004) meta-analysis; heterogeneity across studies; structural volume does not directly measure neurogenesis. Certainty Assessment:: 0.70 raw × 0.85 human-imaging meta-analysis weight = discounted 0.60

8 Gandy et al. 2017 — Pattern Separation as a Marker of Impaired Hippocampal Neurogenesis in MDD

(Gandy et al. 2017)

Full Citation:: Gandy K, Kim S, Sharp C, Gandy L, Schinder AF, Sahay A, Hen R. Pattern separation: a potential marker of impaired hippocampal adult neurogenesis in major depressive disorder. Frontiers in Neuroscience. 2017;11:571. DOI:: 10.3389/fnins.2017.00571 PMID:: 29123464 · PMCID:: PMC5662616 Study Design:: Review/perspective Key Findings::

  • Pattern separation (discriminating similar experiences) is a canonical function of dentate gyrus newborn neurons.
  • Proposes pattern separation as a behavioral marker of impaired adult hippocampal neurogenesis in MDD. Conclusion:: Directly supports the pattern-separation-impaired-in-depression claim that anchors the Peng 2026 cognitive framing. Limitations:: Review/perspective; pattern separation is not exclusively dependent on neurogenesis; mainly rodent-derived inference. Certainty Assessment:: 0.65 raw × 0.70 review weight = discounted 0.46

9 Sorrells et al. 2018 — Human Hippocampal Neurogenesis Drops to Undetectable Levels in Adults (COMPETING/NULL)

(Sorrells et al. 2018)

Full Citation:: Sorrells SF, Paredes MF, Cebrian-Silla A, Sandoval K, Qi D, Kelley KW, James D, Mayer S, Chang J, Auguste KI, Chang EF, Gutierrez AJ, Kriegstein AR, Mathern GW, Oldham MC, Huang EJ, Garcia-Verdugo JM, Yang Z, Alvarez-Buylla A. Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults. Nature. 2018;555(7696):377–381. DOI:: 10.1038/nature25975 PMID:: 29513649 · PMCID:: PMC6179355 Study Design:: Post-mortem multi-method neurogenesis analysis (DCX, Ki67, PCNA) with optimized fixation Key Findings::

  • Hippocampal neurogenesis is robust in children but drops sharply to undetectable or very low levels in adults.
  • Challenges the premise that adult hippocampal neurogenesis persists at functionally meaningful levels. Conclusion:: A central competing/null position that contests the foundation of the stalled-neurogenesis-in-MDD interpretation; must be weighed against Boldrini 2018 and single-nucleus studies. Limitations:: Fixation/method debates; conflicts with Boldrini 2018 and Peng 2026; the adult-neurogenesis question remains unresolved. Certainty Assessment:: 0.75 raw × 0.90 human weight = discounted 0.68

10 Sorrells et al. 2021 — Positive Controls Support Few New Neurons in Adult Hippocampus (COMPETING/NULL)

(Sorrells et al. 2021)

Full Citation:: Sorrells SF, Paredes MF, Zhang Z, Kang G, Pastor-Alonso O, Biagiotti S, Page CE, Sandoval K, Knox A, Connolly A, Huang EJ, Garcia-Verdugo JM, Oldham MC, Yang Z, Alvarez-Buylla A. Positive controls in adults and children support that very few, if any, new neurons are born in the adult human hippocampus. Journal of Neuroscience. 2021;41(12):2554–2565. DOI:: 10.1523/JNEUROSCI.0676-20.2020 PMID:: 33762407 · PMCID:: PMC8018729 Study Design:: Post-mortem analysis with positive controls Key Findings::

  • Using positive controls, concludes very few, if any, new neurons are born in the adult human hippocampus.
  • Strengthens the Sorrells 2018 null position against robust adult human neurogenesis. Conclusion:: Reinforces the competing/null position; the field remains unresolved between the Sorrells null and the persistence-supporting single-nucleus studies. Limitations:: Within-field controversy; cannot fully exclude low-level neurogenesis. Certainty Assessment:: 0.75 raw × 0.85 human weight = discounted 0.64

11 Snyder et al. 2011 — Adult Hippocampal Neurogenesis Buffers Stress and Depressive Behaviour (ANIMAL)

(Snyder et al. 2011)

Full Citation:: Snyder JS, Soumier A, Brewer M, Pickel J, Cameron HA. Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature. 2011;476(7361):458–461. DOI:: 10.1038/nature10287 PMID:: 21814201 · PMCID:: PMC3162077 Study Design:: Transgenic and radiation ablation of adult neurogenesis in mice Key Findings::

  • Neurogenesis-deficient mice show slower glucocorticoid recovery after stress and less dexamethasone suppression — impaired HPA-axis negative feedback.
  • Neurogenesis-deficient mice show increased behavioural despair and anhedonia (decreased sucrose preference). Conclusion:: Directly links adult hippocampal neurogenesis to HPA-axis regulation and depression, the mechanistic backbone of the Peng 2026 stress-related-reprogramming finding. Limitations:: Animal model; HPA-axis role inferred; translatability to humans unproven. Certainty Assessment:: 0.85 raw × 0.50 animal weight = discounted 0.43

12 Anacker & Hen 2017 — Adult Hippocampal Neurogenesis and Cognitive Flexibility (REVIEW)

(Anacker and Hen 2017)

Full Citation:: Anacker C, Hen R. Adult hippocampal neurogenesis and cognitive flexibility – linking memory and mood. Nature Reviews Neuroscience. 2017;18(6):335–346. DOI:: 10.1038/nrn.2017.45 PMID:: 28469276 Study Design:: Review Key Findings::

  • Links adult hippocampal neurogenesis to cognitive flexibility, memory, and mood regulation.
  • Reviews evidence that neurogenesis contributes to pattern separation, cognitive flexibility, and emotional regulation. Conclusion:: Provides the conceptual framework connecting a molecular neurogenesis deficit to the cognitive and mood symptoms of depression. Limitations:: Review; largely rodent-derived evidence; senior author overlap with Boldrini/Peng groups. Certainty Assessment:: 0.80 raw × 0.80 review weight = discounted 0.64

15 Buiting et al. 2016 — Angelman Syndrome: Insights into a Rare Neurogenetic Disorder (OVERVIEW)

(Buiting, Williams, and Horsthemke 2016)

Full Citation:: Buiting K, Williams C, Horsthemke B. Angelman syndrome — insights into a rare neurogenetic disorder. Nature Reviews Neurology. 2016;12(10):584–593. DOI:: 10.1038/nrneurol.2016.133 PMID:: 27615419 Study Design:: Authoritative clinical and molecular review Key Findings::

  • Angelman syndrome (AS) results from UBE3A loss-of-function at 15q11-q13, typically via maternal deletion or imprinting-centre defects.
  • Clinical features: severe developmental delay, absent speech, ataxia, epilepsy, microcephaly, and a characteristic happy demeanor.
  • Molecular consequences of UBE3A (E6AP E3 ubiquitin ligase) loss span proteostasis, GABAergic dysfunction, and mitochondrial/energy deficits.
  • Ube3a-deficient mice show reduced tonic GABA-A inhibition and synaptic abnormalities. Conclusion:: Establishes the disease framework used to assess pathophysiological overlap with ME/CFS, particularly the GABAergic, mitochondrial, and sleep domains. Limitations:: General-population expert review; AS is a rare neurogenetic disorder, so any ME/CFS overlap is indirect and must be earned by mechanism, not co-morbidity. Certainty Assessment:: 0.85 raw × 0.80 general-population review weight = discounted 0.68

16 Su et al. 2011 — Mitochondrial Dysfunction in CA1 Neurons of the UBE3A-Deficient Mouse (ANIMAL)

(Su et al. 2011)

Full Citation:: Su H, Fan W, Coskun PE, Vesa J, Gold JA, Jiang Y, Potluri P, Wallace DC, Gibson J, Kimonis VE. Mitochondrial dysfunction in CA1 hippocampal neurons of the UBE3A deficient mouse model for Angelman syndrome. Neuroscience Letters. 2011;487(2):129–133. DOI:: 10.1016/j.neulet.2009.06.079 PMID:: 19563863 Study Design:: Animal model (Ube3a maternal-null mouse), biochemical mitochondrial analysis Key Findings::

  • Hippocampal CA1 neurons from UBE3A-deficient mice show reduced ATP levels.
  • Mitochondrial dysfunction and impaired oxidative phosphorylation accompany UBE3A loss. Conclusion:: Links UBE3A loss to impaired cellular energy reserve, bridging AS to the mitochondrial/energy-deficit component of ME/CFS pathophysiology. Limitations:: Animal model only; CA1-hippocampus focus; indirect relevance to ME/CFS (no AS-ME/CFS co-occurrence data). Certainty Assessment:: 0.65 raw × 0.50 animal weight = discounted 0.33

18 Simchi et al. 2023 — Elevated ROS in Early Angelman Syndrome Development (ANIMAL)

(Simchi et al. 2023)

Full Citation:: Simchi L, Gupta PK, Feuermann Y, Kaphzan H. Elevated ROS levels during the early development of Angelman syndrome alter the apoptotic capacity of the developing neural precursor cells. Molecular Psychiatry. 2023;28(6):2382–2397. DOI:: 10.1038/s41380-023-02038-7 PMID:: 36991133 Study Design:: Animal model (Ube3a-deficient neural precursor cells) Key Findings::

  • Early-development Ube3a-deficient neural precursor cells show elevated reactive oxygen species (ROS).
  • Elevated ROS alters the apoptotic capacity of developing neural precursors. Conclusion:: Establishes an oxidative-stress consequence of UBE3A loss during neurodevelopment, relevant to the oxidative-stress/energy component of ME/CFS. Limitations:: Animal/in-vitro precursor cells; developmental (not adult) focus; indirect relevance to ME/CFS. Certainty Assessment:: 0.60 raw × 0.50 animal weight = discounted 0.30

19 Qu et al. 2024 — Sleep Disturbance in Angelman Syndrome Patients (SYMPTOM OVERLAP)

(Qu et al. 2024)

Full Citation:: Qu S, Wang J, Guan X, Song C, Wang X. Sleep disturbance in Angelman syndrome patients. Orphanet Journal of Rare Diseases. 2024;19(1):146. DOI:: 10.1186/s13023-024-03154-5 PMID:: 38580983 Study Design:: Clinical characterization of sleep disturbance Key Findings::

  • Angelman syndrome patients show significant sleep disturbance, including reduced total sleep and fragmented sleep.
  • Abnormal sleep architecture is common. Conclusion:: Sleep disturbance is a shared symptom domain between AS and ME/CFS, providing a symptom-level (not necessarily mechanism-level) overlap. Limitations:: AS-specific clinical population; symptom-level relevance to ME/CFS sleep symptoms only; no ME/CFS co-occurrence. Certainty Assessment:: 0.60 raw × 0.80 general-population weight = discounted 0.48

20 Watanabe et al. 2026 — Region-Dependent Tonic Inhibition in AS Model Mice (ANIMAL; GABAergic BRIDGE)

(Watanabe et al. 2026)

Full Citation:: Watanabe M, Goto T, Miyoshi R, Nakakubo S, Hiramatsu Y, Nakajima R, Kondo A, Higashiyama K, Yamakawa K. Region-dependent differences in tonic inhibition underlie epileptic features in Angelman syndrome model mice. Epilepsia. 2026. DOI:: 10.1002/epi.70307 PMID:: 42227760 Study Design:: Animal model (Ube3a-deficient mice), electrophysiology Key Findings::

  • Region-dependent reduction in tonic GABA-A receptor-mediated inhibition in Ube3a-deficient mice.
  • This GABAergic disinhibition underlies epileptic features of Angelman syndrome. Conclusion:: Directly demonstrates GABAergic disinhibition downstream of UBE3A loss — a mechanistic bridge to the excitatory/inhibitory imbalance proposed in ME/CFS (see Wirth 2026). Limitations:: Animal model; epilepsy-focused; GABAergic-in-ME/CFS is a proposal, not an established finding. Certainty Assessment:: 0.60 raw × 0.50 animal weight = discounted 0.30

21 Kurmashev 2026 — UBE3A Dosage Imbalance Linking AS and Dup15q Autism (REVIEW; PROTEOSTASIS)

(Kurmashev 2026)

Full Citation:: Kurmashev R. UBE3A Dosage Imbalance as a Molecular Framework Linking Angelman Syndrome and Dup15q-Associated Autism Phenotypes. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2026. DOI:: 10.1002/ajmg.b.70025 PMID:: 42464451 Study Design:: Review Key Findings::

  • Proposes UBE3A dosage imbalance as a unifying molecular framework linking AS (loss) and Dup15q autism (duplication).
  • Both loss- and gain-of-function of the E6AP ubiquitin-ligase pathway can produce overlapping neurodevelopmental outcomes. Conclusion:: Provides the proteostasis/dosage-sensitivity context for UBE3A, relevant to proteostasis-dysfunction hypotheses in ME/CFS. Limitations:: Review; autism-focused; AS-ME/CFS relevance indirect. Certainty Assessment:: 0.65 raw × 0.80 review weight = discounted 0.52

22 Khasnavis et al. 2024 — Guanfacine + NAC for Cognitive Deficits After TBI (DIRECT COMBINATION)

(Khasnavis et al. 2024)

Full Citation:: Khasnavis S, Belliveau T, Arnsten A, Fesharaki-Zadeh A. Combined Use of Guanfacine and N-acetylcysteine for the Treatment of Cognitive Deficits After Traumatic Brain Injury. Neurotrauma Reports. 2024;5(1):226–231. DOI:: 10.1089/neur.2023.0124 PMID:: 38524728 Study Design:: Case series (n=2), neuropsychological testing pre/post Key Findings::

  • Same Yale group fixed combination as the Long-COVID anchor: guanfacine (α2A-adrenoceptor agonist) + N-acetylcysteine (NAC).
  • Treated post-TBI cognitive deficits; improved attention, processing speed, memory, and executive function.
  • Minimal side effects in both persons. Conclusion:: Demonstrates the mechanistic catecholamine (guanfacine strengthens PFC) × Nrf2/antioxidant (NAC) bridge logic applied outside Long-COVID, supporting the fixed combination as a general cognitive-recovery intervention. Limitations:: n=2 case series; uncontrolled; TBI population, not ME/CFS. Certainty Assessment:: 0.40 raw × 0.75 general-population weight = discounted 0.30

23 Fesharaki-Zadeh et al. 2025 — Guanfacine + NAC + Donepezil in Severe TBI (DIRECT COMBINATION EXTENSION)

(Fesharaki-Zadeh et al. 2025)

Full Citation:: Fesharaki-Zadeh A, Belliveau T, Pietrzak RH, Arnsten A. A novel multimodal pharmacologic approach using guanfacine, N-acetylcysteine, and donepezil in severe TBI: a case series. Frontiers in Rehabilitation Sciences. 2025;6:1648002. DOI:: 10.3389/fresc.2025.1648002 PMID:: 41211476 Study Design:: Case series, MoCA pre/post Key Findings::

  • Extends the guanfacine + NAC combination with donepezil (GND) to severe TBI.
  • Frames guanfacine as enhancing prefrontal cortical function; NAC as antioxidant/glutamate modulator with neuroprotective effects.
  • Cites the Long-COVID anchor ((Fesharaki-Zadeh, Lowe, and Arnsten 2023)) as prior evidence for the guanfacine/NAC combination. Conclusion:: Corroborates the multimodal bridge rationale and the guanfacine+NAC fixed-combination logic from a second, independent publication by the same group. Limitations:: Small case series; uncontrolled; TBI, not ME/CFS. Certainty Assessment:: 0.40 raw × 0.75 general-population weight = discounted 0.30

24 Okamoto et al. 2024 — Guanfacine Response in Hyperadrenergic POTS (CATECHOLAMINE ARM)

(Okamoto et al. 2024)

Full Citation:: Okamoto LE, Urechie V, Rigo S, et al. Hyperadrenergic Postural Tachycardia Syndrome: Clinical Biomarkers and Response to Guanfacine. Hypertension. 2024;81(11):2237–2247. DOI:: 10.1161/HYPERTENSIONAHA.124.23035 PMID:: 39109428 Study Design:: Phenotyping cohort (n=28) + uncontrolled treatment cohort (n=38) Key Findings::

  • Guanfacine (central sympatholytic, α2A agonist) reduced chronic fatigue (PROMIS Fatigue) and improved orthostatic tolerance in hyperadrenergic POTS.
  • 85% of hyperadrenergic patients improved vs 44% nonhyperadrenergic (P=0.016).
  • Hyperadrenergic subset identified by diastolic BP rise exceeding 17 mmHg on Valsalva phase 2. Conclusion:: Directly supports the catecholamine/α2A arm of the bridge in POTS, a population highly comorbid with ME/CFS. Authors filed a patent application for guanfacine in CFS (COI). Limitations:: Uncontrolled treatment cohort; POTS, not ME/CFS per se; biomarker-driven subset. Certainty Assessment:: 0.60 raw × 0.80 POTS weight = discounted 0.48

25 Cherneva et al. 2025 — NAC CNS Mechanisms, Nrf2 + Adrenergic/Dopaminergic Intersection (Nrf2 ARM)

(Cherneva et al. 2025)

Full Citation:: Cherneva DI, Kehayova G, Dimitrova S, Dragomanova S. The Central Nervous System Modulatory Activities of N-Acetylcysteine: A Synthesis of Two Decades of Research. Current Issues in Molecular Biology. 2025;47(9):710. DOI:: 10.3390/cimb47090710 PMID:: 41020832 Study Design:: Mechanistic review Key Findings::

  • NAC: antioxidant via glutathione replenishment, Nrf2-ARE signaling, mitochondrial redox modulation, ferroptosis inhibition.
  • Anti-neuroinflammatory: inhibits cytokines, iNOS, microglial activation.
  • Modulates glutamatergic, dopaminergic, GABAergic, serotonergic, cholinergic, AND adrenergic neurotransmitter systems. Conclusion:: Provides the explicit biochemical bridge: NAC’s Nrf2/redox arm intersects catecholamine/adrenergic transmission — the mechanism the guanfacine+NAC combination targets in ME/CFS. Limitations:: Review; indirect to ME/CFS; no direct combination data. Certainty Assessment:: 0.55 raw × 0.75 general-population weight = discounted 0.41

26 Barlattani et al. 2025 — NAC + Acetyl-L-carnitine in Post-COVID Syndrome (Nrf2 ARM IN LONG-COVID)

(Barlattani et al. 2025)

Full Citation:: Barlattani T, Celenza G, Cavatassi A, et al. Neuropsychiatric Manifestations of COVID-19 Disease and Post COVID Syndrome: The Role of N-acetylcysteine and Acetyl-L-carnitine. Current Neuropharmacology. 2025;23(6):686–704. DOI:: 10.2174/011570159X343115241030094848 PMID:: 39506442 Study Design:: Review Key Findings::

  • NAC + acetyl-L-carnitine in Post-COVID Syndrome (PCS)/Long-COVID neuropsychiatric symptoms: brain fog, fatigue, cognitive impairment.
  • NAC acts via glutamatergic system (xCT-mGluR2 network) and antioxidant/redox pathways; evidence of relieving cognitive symptoms in PCS. Conclusion:: Supports the NAC arm of the bridge in the Long-COVID population most relevant to ME/CFS. Limitations:: Review; no direct guanfacine+NAC combination data. Certainty Assessment:: 0.50 raw × 0.85 Long-COVID weight = discounted 0.43

27 Dastan et al. 2025 — Saffron for Chronic Fatigue in COPD Patients (DIRECT FATIGUE RCT)

(Dastan et al. 2025)

Full Citation:: Dastan F, Salamzadeh J, Heshmatnia J, Mahmoudian R. Evaluating the Effects of Crocus sativus L. Herbal Product on Chronic Fatigue Syndrome in Patients with Chronic Obstructive Pulmonary Disease. Iranian Journal of Pharmaceutical Research. 2025;24(1):e165333. DOI:: 10.5812/ijpr-165333 PMID:: 41477128 Study Design:: Randomized, double-blind, placebo-controlled trial (saffron 30 mg twice daily x 8 weeks; n=37 intervention, n=34 placebo) Key Findings::

  • Saffron significantly improved chronic fatigue syndrome (Manchester COPD Fatigue Scale, \(p < 0.001\)) and CRQ total (\(p < 0.001\)) in COPD patients.
  • QOL improved (SGRQ, P=0.012); no effect on dyspnea subscale (P=0.38). Conclusion:: Strongest direct saffron-fatigue RCT, but population is secondary CFS comorbid with COPD, not primary ME/CFS. Limitations:: Comorbid secondary fatigue; COPD population; no primary ME/CFS patients; single center. Certainty Assessment:: 0.45 raw × 0.40 comorbid-fatigue weight = discounted 0.18

28 Moghimi Dehkordi et al. 2026 — Saffron for Sleep and Fatigue in Pulmonary Sarcoidosis (DIRECT FATIGUE RCT)

(Moghimi Dehkordi et al. 2026)

Full Citation:: Moghimi Dehkordi Z, Salamzadeh J, Tavakoli-Ardakani M, Abedini A, Dastan F. Efficacy of a Saffron-Based (Crocus sativus L.) Herbal Supplement on Sleep Disturbances in Pulmonary Sarcoidosis Patients. Iranian Journal of Pharmaceutical Research. 2026;25(1):e169041. DOI:: 10.5812/ijpr-169041 PMID:: 42483079 Study Design:: Single-blind randomized controlled trial (saffron 30 mg twice daily x 60 days; N=76, 72 completed) Key Findings::

  • Saffron improved sleep (PSQI, GSDS), reduced daytime sleepiness (ESS) and fatigue (FAS, PROMIS-fatigue; all \(p < 0.001\)).
  • Improved SF-12 physical and mental component scores; no serious adverse events. Conclusion:: Reduces fatigue and improves sleep in a chronic inflammatory lung disease, supporting a fatigue-domain effect; not primary ME/CFS. Limitations:: Single-blind; sarcoidosis population; secondary/symptom-level fatigue. Certainty Assessment:: 0.42 raw × 0.40 comorbid-fatigue weight = discounted 0.17

29 Hajhashemy et al. 2026 — Saffron in Parkinson’s Disease: Fatigue, Inflammation, Oxidative Stress (FATIGUE + INFLAMMATION RCT)

(Hajhashemy, Bagherniya, and Sadeghi 2026)

Full Citation:: Hajhashemy Z, Bagherniya M, Sadeghi O. The effect of saffron supplementation on indices of oxidative stress, inflammation, mental health, and quality of life in patients with Parkinson’s disease. Food & Function. 2026;17(2):889–901. DOI:: 10.1039/d5fo01924a PMID:: 41439298 Study Design:: Triple-blind randomized controlled trial (saffron 100 mg/day x 12 weeks; N=92) Key Findings::

  • Saffron significantly reduced CRP (-3.84 mg/L, \(p < 0.001\)), fatigue (adjusted MD -9.20, \(p < 0.001\)), depression, anxiety, and distress.
  • Improved cognitive status and sleep quality. Conclusion:: Reduces fatigue and systemic inflammation (CRP) in a chronic oxidative-stress population — mechanism-relevant to ME/CFS inflammatory/oxidative overlap. Limitations:: Parkinson’s disease population, not ME/CFS; distinct disease. Certainty Assessment:: 0.45 raw × 0.45 cross-disease weight = discounted 0.20

30 Amadieu et al. 2025 — Saffron for Subclinical Depression/Fatigue: A Null Trial (NULL RESULT)

(Amadieu et al. 2025)

Full Citation:: Amadieu C, Leyrolle Q, Farneti M, et al. Effect of saffron extract supplementation on mood in healthy adults with subclinical symptoms of depression: a randomized, double-blind, placebo-controlled trial. American Journal of Clinical Nutrition. 2025;122(6):1625–1635. DOI:: 10.1016/j.ajcnut.2025.09.050 PMID:: 41047129 Study Design:: Randomized, double-blind, placebo-controlled trial (6 weeks; N=51 healthy adults, subclinical depressive symptoms; NCT05690126) Key Findings::

  • Saffron did NOT significantly affect the primary composite outcome (depression, anxiety, fatigue) nor individual symptoms including fatigue.
  • Only autoperceived mental health improved (SF-12 mental, P=0.04); no effect on inflammatory markers or HPA-axis reactivity. Conclusion:: CRITICAL NULL: saffron does not improve fatigue/depression in healthy subclinical adults; the mental-health effect is weak and unconfirmed. Limitations:: Healthy subclinical population; small sample; 6 weeks. Certainty Assessment:: 0.60 raw × 0.70 healthy-adult weight = discounted 0.42

31 Dimech 2026 — The Role of Saffron in Depression (CONTEXT REVIEW)

(Dimech 2026)

Full Citation:: Dimech L. The Role of Saffron in the Treatment of Depression: A Literature Review. Cureus. 2026;18(3):e104594. DOI:: 10.7759/cureus.104594 PMID:: 41939549 Study Design:: Literature review (RCTs, meta-analyses, safety, mechanisms) Key Findings::

  • Across placebo-controlled trials in mild-to-moderate depression, saffron (commonly 30 mg/day x ~6 weeks) produces clinically meaningful HAM-D reductions.
  • Head-to-head studies suggest comparable short-term efficacy to fluoxetine/imipramine but are underpowered. Conclusion:: Establishes saffron’s serotonergic/mood-modulating profile; GENERAL depression evidence, not ME/CFS- or fatigue-specific. Limitations:: General depression focus; underpowered head-to-head trials; no ME/CFS data. Certainty Assessment:: 0.55 raw × 0.85 general-mood weight = discounted 0.47

32 Căuș et al. 2026 — Herbal Supplement Safety: Serotonin Syndrome and Drug Interactions (HARM)

(Căuș, Lupoae, and Chițescu 2026)

Full Citation:: Căuș MN, Lupoae M, Chițescu CL. Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data. Pharmaceuticals (Basel). 2026;19(3):399. DOI:: 10.3390/ph19030399 PMID:: 41901246 Study Design:: Narrative clinical review Key Findings::

  • Herbal serotonergic supplements (incl. Crocus sativus) carry clinically relevant risks: serotonin syndrome (esp. with SSRIs/MAOIs), CYP450-mediated drug interactions, excessive sedation, product adulteration. Conclusion:: Establishes the serotonergic-herb interaction warning relevant to the paper’s serotonin-syndrome and MAOI/SSRI contraindication content. Limitations:: Narrative review; not saffron-specific in all detail. Certainty Assessment:: 0.55 raw × 0.85 clinical-review weight = discounted 0.47

33 Alshdefat et al. 2026 — Saffron and Pregnancy Safety (PREGNANCY HARM)

(Alshdefat et al. 2026)

Full Citation:: Alshdefat A, Ayed A, Aqtam I, Ibitoye O, Vincent S, Furqani AA. Saffron and Pregnancy: Cultural Practices, Beliefs, and Safety Evidence: An Integrative Review. Journal of Evidence-Based Integrative Medicine. 2026;31:2515690X261455162. DOI:: 10.1177/2515690X261455162 PMID:: 42186868 Study Design:: Integrative review (12 studies) Key Findings::

  • Low-dose saffron (~250 mg/day) may facilitate cervical ripening, reduce labor pain/anxiety, shorten labor — dose-dependent.
  • Higher doses or occupational exposure linked to uterine stimulation (potential abortifacient/uterine-contraction risk). Conclusion:: Mandatory harm reference for a nutraceutical treatment topic: cautions against saffron in pregnancy, especially at high dose. Limitations:: Integrative review; limited high-quality trial data. Certainty Assessment:: 0.55 raw × 0.85 clinical-review weight = discounted 0.47

34 De la Fuente Muñoz et al. 2023 — Saffron Shifts Kynurenine Pathway Toward Melatonin (KEY TRYPTOPHAN-KYNURENINE AXIS; ANIMAL)

(De la Fuente Muñoz et al. 2023)

Full Citation:: De la Fuente Muñoz M, Román-Carmena M, Amor S, et al. Effects of Supplementation with the Standardized Extract of Saffron (affron) on the Kynurenine Pathway and the Synthesis of Melatonin in Rats. Antioxidants (Basel). 2023;12(8):1619. DOI:: 10.3390/antiox12081619 PMID:: 37627614 Study Design:: Animal model (rat), standardized saffron extract (affron, 150 mg/kg x 7 days) Key Findings::

  • Affron DECREASED SERUM KYNURENINE and increased circulating melatonin, testosterone, and c-HDL.
  • Framed against the tryptophan/kynurenine/serotonin/melatonin axis: saffron shifts balance away from kynurenine toward melatonin/serotonin. Conclusion:: DIRECT mechanism-level bridge to the paper’s serotonergic-bottleneck and tryptophan-kynurenine models (IDO/kynurenine-dopamine, Phair IDO trap). Limitations:: Animal model; 7 days; standardized extract, not whole saffron. Certainty Assessment:: 0.35 raw × 0.30 animal weight = discounted 0.11

35 Mohammadi et al. 2023 — Crocin/Crocetin Bind SERT and Inhibit NMDA (KEY SEROTONIN-REUPTAKE + NMDA MECHANISM; ANIMAL)

(Mohammadi et al. 2023)

Full Citation:: Mohammadi S, Naseri M, Faridi N, Zareie P, Zare L, Mirnajafi-Zadeh J, Bathaie SZ. Saffron carotenoids reversed the UCMS-induced depression and anxiety in rats: Behavioral and biochemical parameters, and inhibition of NMDA receptor. Phytomedicine. 2023;119:154989. DOI:: 10.1016/j.phymed.2023.154989 PMID:: 37506574 Study Design:: Animal model (UCMS rat), crocin and crocetin vs fluoxetine Key Findings::

  • Crocin/crocetin bind the SEROTONIN TRANSPORTER (SLC6A4) at the same site as fluoxetine and increase serum serotonin.
  • Crocetin inhibits NMDA NR2B receptor (ifenprodil site), reducing NMDA amplitude; increases hippocampal CREB/ERK/BDNF/p11/5-HT1B. Conclusion:: Molecular basis for saffron’s SSRI-like serotonergic action AND an NMDA/excitotoxicity-modulation arm — relevant to serotonergic-bottleneck and kynurenine-NMDA content. Limitations:: Animal model; depression (not ME/CFS) model. Certainty Assessment:: 0.35 raw × 0.30 animal weight = discounted 0.11

36 Wauquier et al. 2022 — Human Saffron Metabolites Inhibit SERT and Protect Neurons (KEY HUMAN SERT-MECHANISM; EX VIVO)

(Wauquier et al. 2022)

Full Citation:: Wauquier F, Boutin-Wittrant L, Pourtau L, et al. Circulating Human Serum Metabolites Derived from the Intake of a Saffron Extract Protect Human Neurons from Oxidative Stress-Induced Neurotoxicity. Nutrients. 2022;14(7):1511. DOI:: 10.3390/nu14071511 PMID:: 35406124 Study Design:: Ex vivo human (post-ingestion serum metabolites on human neurons) Key Findings::

  • Human saffron metabolites protect neurons from oxidative-stress neurotoxicity (preserve viability, increase BDNF), stimulate dopamine/serotonin release.
  • Inhibit SERT expression and downregulate serotonin metabolism. Conclusion:: HUMAN-based evidence for saffron’s serotonergic (SERT-inhibiting) and oxidative-stress-protective actions — bridge to serotonergic-bottleneck and oxidative-stress content. Limitations:: Ex vivo metabolomics of human post-ingestion serum; not in vivo clinical outcome. Certainty Assessment:: 0.50 raw × 0.55 human-ex-vivo weight = discounted 0.28

37 De Monte et al. 2014 — Saffron’s Safranal and Crocin Inhibit Human MAO (MECHANISM — hMAO INHIBITION; IN VITRO)

(De Monte et al. 2014)

Full Citation:: De Monte C, Carradori S, Chimenti P, et al. New insights into the biological properties of Crocus sativus L.: chemical modifications, human monoamine oxidases inhibition and molecular modeling. European Journal of Medicinal Chemistry. 2014;82:164–171. DOI:: 10.1016/j.ejmech.2014.05.038 PMID:: 24904963 Study Design:: In vitro / in silico enzyme assay (hMAO-A, hMAO-B) Key Findings::

  • Crocin and safranal inhibit human monoamine oxidases (hMAO-A and hMAO-B), with distinct docking binding modes. Conclusion:: Establishes saffron’s MAO-inhibitory action — relevant to serotonergic/dopaminergic mechanism content AND a harm consideration (MAOI-like action raises serotonin-syndrome risk with SSRIs/serotonergic drugs). Limitations:: In vitro/in silico; enzyme assay, not clinical. Certainty Assessment:: 0.40 raw × 0.35 in-vitro weight = discounted 0.14

38 Monchaux de Oliveira et al. 2026 — Saffron Bioactives: Safranal Modulates Kynurenine Pathway (KEY PRECLINICAL KYNURENINE AXIS; ANIMAL)

(Monchaux de Oliveira et al. 2026)

Full Citation:: Monchaux de Oliveira C, Vignault A, Guille A, et al. Exploring the neurofunctional potential of saffron bioactives: from mood-related behavioral modulation to brain access of its compounds. Food & Function. 2026;17(6):2800–2818. DOI:: 10.1039/d5fo04830c PMID:: 41758529 Study Design:: Preclinical mouse study (crocins, safranal) Key Findings::

  • Crocins primarily modulate the dopaminergic system.
  • SAFRANAL selectively downregulates NEUROTOXIC components of the kynurenine pathway, shifting neurotoxic/neuroprotective balance toward neuroprotection. Conclusion:: Direct molecular link from saffron to kynurenine-pathway modulation — relevant to the paper’s IDO/kynurenine-NMDA/neurotoxic-quinolinic-acid content. Limitations:: Animal model; acute single oral dose. Certainty Assessment:: 0.35 raw × 0.30 animal weight = discounted 0.11

39 Horvath et al. 2026 — Saffron Remodels Gut-Microbial Tryptophan Metabolism (KEY MICROBIOME-TRYPTOPHAN AXIS; IN VITRO CONSORTIUM)

(Horvath et al. 2026)

Full Citation:: Horvath AE, Grozis M, Baker PRS, et al. Saffron Alters Microbial Amino Acid Metabolism and Neurotransmitter Production in a Defined Gut Consortium. Food Science & Nutrition. 2026;14(4):e71694. DOI:: 10.1002/fsn3.71694 PMID:: 41948379 Study Design:: In vitro defined human commensal consortium (anaerobic bioreactors) Key Findings::

  • Saffron reduced microbial tryptophan while increasing its downstream products TRYPTAMINE and INDOLE ACETIC ACID.
  • Elevated neuroactive compounds (GABA, glutamate, glycine, dopamine); decreased L-DOPA, tyrosine, anthranilic acid; shifted SCFA profiles. Conclusion:: Directly demonstrates saffron modulates GUT-MICROBIAL TRYPTOPHAN METABOLISM — the tryptophan/aryl-hydrocarbon-receptor/indole pathway the paper covers. Limitations:: In vitro defined consortium, not in vivo human; defined strains may not reflect whole gut ecosystem. Certainty Assessment:: 0.40 raw × 0.35 ex-vivo-microbial weight = discounted 0.14

40 Lang et al. 2025 — Saffron Improves Sleep via the Gut-Microbiota-Brain Axis (MICROBIOME-SLEEP AXIS; HUMAN PILOT)

(Lang et al. 2025)

Full Citation:: Lang L, Ditton A, Stanescu A, et al. A standardised saffron extract improves subjective and objective sleep quality in healthy older adults with sleep complaints: a randomised, placebo-controlled pilot study. Food & Function. 2025;16(17):6817–6832. DOI:: 10.1039/d5fo00917k PMID:: 40762630 Study Design:: Randomised placebo-controlled pilot (4 weeks, saffron 30 mg/day; N=52 healthy older adults) Key Findings::

  • Saffron improved subjective sleep quality (P=0.02), sleep efficiency (P=0.04), and reduced sleep-onset latency (objective, P=0.003).
  • Microbiome (LEfSe): increased Faecalibacterium, Lachnoclostridium, Prevotella, UBA1819, Oscillibacter; decreased Dialister. Conclusion:: Saffron modulates the gut-microbiota-brain/sleep axis — relevant to ME/CFS sleep and gut-microbiome content; healthy older adults, not ME/CFS. Limitations:: Healthy older adults; pilot size; sleep-only outcome. Certainty Assessment:: 0.50 raw × 0.65 healthy-adult pilot weight = discounted 0.33

41 Esteban et al. 2026 — AhR Agonists in the ME/CFS Gut Microbiome (ANCHOR DIRECT ME/CFS AHR STUDY)

(Esteban et al. 2026)

Full Citation:: Esteban DJ, Conrad B, Cullinan A, Luong S, Albaum J, Wilk V. Tryptophan Metabolism and Aryl-Hydrocarbon Receptor Agonists in the Gut Microbiome of People With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. MicrobiologyOpen. 2026;15(3):e70333. DOI:: 10.1002/mbo3.70333 PMID:: 42325052 Study Design:: Cross-sectional metabolomics + stool ex vivo AhR-reporter activation in ME/CFS vs controls Key Findings::

  • Lower microbial diversity and altered community structure in ME/CFS; changes in a microbial subcommunity correlated with tryptophan metabolites.
  • Nine stool metabolites elevated in ME/CFS, including three AhR agonists.
  • KEY PARTIAL-NULL: AhR activation did NOT differ between ME/CFS and controls overall, but was elevated in people with neurocognitive symptoms regardless of underlying disease. Conclusion:: Directly establishes the AhR-gut-microbiome-tryptophan axis as a candidate common mechanism, specifically associated with neurocognitive symptoms in ME/CFS. Limitations:: Single study; the null on overall AHR activation tempers any claim that ME/CFS has uniform AhR hyperactivation; the symptom-subgroup finding needs replication. Certainty Assessment:: 0.70 raw × 1.00 ME/CFS weight = discounted 0.70

42 Tian et al. 2024 — Indole-Derivative Metabolic Diversity as ME/CFS Biomarker (ME/CFS GUT INDOLE; PREPRINT)

(H. Tian et al. 2024)

Full Citation:: Tian H, Wang L, Aiken E, Ortega RJV, Hardy R, Placek L, Kozhaya L, Unutmaz D, Oh J, Yao X. Fast Targeted Metabolomics for Analyzing Metabolic Diversity of Bacterial Indole Derivatives in ME/CFS Gut Microbiome. bioRxiv. 2024. doi:10.1101/2024.07.29.605643. DOI:: 10.1101/2024.07.29.605643 PMID:: 39131327 Study Design:: Targeted metabolomics (LC-PRM) of bacterial indole pathway metabolites; 10 ME/CFS + 10 controls; machine-learning classification Key Findings::

  • Indole-derivative concentration distributions (indole-3-acrylate, indole-3-aldehyde) distinguished B. uniformis strain clusters.
  • Moderate ME/CFS vs control classification via AdaBoost-LOOCV (mean accuracy 0.65). Conclusion:: Metabolic diversity of gut-bacterial indole (AhR-ligand) derivatives is a potential biomarker for classifying ME/CFS samples. Limitations:: Preprint; very small sample (n=10/group); moderate classification accuracy; not yet peer-reviewed or replicated. Certainty Assessment:: 0.35 raw × 1.00 ME/CFS weight = discounted 0.35

43 Chojnacki et al. 2025 — Tryptophan/AhR-Ligand Metabolites in IBS with CFS (CFS + IBS TRYPTOPHAN METABOLITES)

(Chojnacki et al. 2025)

Full Citation:: Chojnacki M, Blonska A, Kaczka A, Chojnacki J, Walecka-Kapica E, Romanowska N, Przybylowska-Sygut K, Poplawski T. Assessment of the Gut Microbiome in Patients with Coexisting Irritable Bowel Syndrome and Chronic Fatigue Syndrome. Nutrients. 2025;17(13):2232. DOI:: 10.3390/nu17132232 PMID:: 40647335 Study Design:: Cross-sectional; 80 women (40 IBS+CFS, 40 IBS-only); GA-map dysbiosis test + LC-MS/MS urinary tryptophan metabolites Key Findings::

  • IBS+CFS group showed greater microbial diversity, higher breath methane, elevated urinary quinolinic acid, xanthurenic acid, 3-indoxyl sulfate (an AhR ligand), and HVA; lower 5-HIAA and kynurenine.
  • Fatigue severity positively correlated with urinary xanthurenic and quinolinic acid. Conclusion:: Links gut-microbial tryptophan/AhR-ligand metabolites (notably 3-indoxyl sulfate) and neuroactive kynurenine derivatives to CFS fatigue in a comorbid IBS population. Limitations:: Comorbid IBS+CFS (not primary ME/CFS); women only; hypothesis-generating; cross-sectional (no causality). Certainty Assessment:: 0.50 raw × 1.00 CFS cohort (comorbid) weight = discounted 0.50

44 Yan et al. 2026 — Dendrobium Restores Indole AhR-Ligands in Rat Chronic Fatigue (ANIMAL TRYPTOPHAN/INDOLE MODEL)

(Yan et al. 2026)

Full Citation:: Yan M, Shi M, Li C, Yu B, Zhou H, Su J, Yu J, Lv G, Chen S. Effects of Dendrobium officinale on chronic fatigue in rats: Modulation of tryptophan metabolism. Journal of Ethnopharmacology. 2026;365:121527. DOI:: 10.1016/j.jep.2026.121527 PMID:: 41861923 Study Design:: Rat chronic-fatigue model (poor-lifestyle induced); 16S rRNA + LC-MS tryptophan/indole metabolomics; 5 groups (control, model, 3 doses) Key Findings::

  • Dendrobium officinale extract increased gut TRP-derived indole metabolites — indole, indole-3-acetic acid, indole-3-propionic acid, indole-3-aldehyde (all AhR ligands).
  • Restored the inhibited kynurenine pathway and alleviated fatigue/depression-like behavior. Conclusion:: Gut-microbial indole metabolites (AhR ligands) track and modulate fatigue state in an animal model, supporting the relevance of the AhR-microbiome axis to fatigue. Limitations:: Animal model (rat); intervention (Dendrobium) is not a mechanism of ME/CFS per se; cross-species translation gap. Certainty Assessment:: 0.45 raw × 0.50 animal weight = discounted 0.23

45 Rothhammer & Quintana 2019 — The AHR as an Environmental-Immune Integrator (LANDMARK AHR-IMMUNOLOGY REVIEW)

(Rothhammer and Quintana 2019)

Full Citation:: Rothhammer V, Quintana FJ. The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease. Nature Reviews Immunology. 2019;19(3):184-197. DOI:: 10.1038/s41577-019-0125-8 PMID:: 30718831 Study Design:: Authoritative expert review Key Findings::

  • AHR is a ligand-activated transcription factor integrating environmental, dietary, microbial, and metabolic cues.
  • Controls transcriptional programmes in a ligand-specific, cell-type-specific, context-specific manner across the immune system, gut immune system, and gut-brain axis.
  • Discusses therapeutic potential of targeting AHR in neurological and autoimmune disorders. Conclusion:: Provides the mechanistic foundation for how gut-microbial AhR ligands modulate immune differentiation (Th17/Treg) and barrier function — the core of the AhR hypothesis. Limitations:: Review; general biology; not ME/CFS-specific. Certainty Assessment:: 0.85 raw × 0.75 general-review weight = discounted 0.64

46 Tian et al. 2026 — Ligand-Specific Duality of AhR in Cognitive Health (AHR HARM + NEUROPROTECTION)

(C. Tian et al. 2026)

Full Citation:: Tian C, Yang S, Zhang X, Yan H. Ligand-specific duality of aryl hydrocarbon receptor signaling in cognitive health: from environmental neurotoxicity to microbiome-mediated neuroprotection. Frontiers in Neuroscience. 2026;20:1823961. DOI:: 10.3389/fnins.2026.1823961 PMID:: 42422257 Study Design:: Systematic review Key Findings::

  • Environmental polycyclic aromatic hydrocarbons drive sustained high-affinity AhR activation (NF-kB neuroinflammation, NLRP3, oxidative stress, synaptic dysfunction — neurotoxic).
  • Gut-microbiota-derived tryptophan metabolites (indole-3-propionic acid, kynurenic acid) drive transient low-affinity AhR activation (anti-inflammatory, neurogenesis, BBB integrity — neuroprotective).
  • Outcome depends on ligand pharmacokinetics, cell type, temporal dynamics, and co-factor availability. Conclusion:: Explains how the same receptor can mediate both harm and protection — the basis for the partial-null finding in Esteban2026 and for harm/adverse-effect considerations of AhR agonists. Limitations:: Review; general biology; not ME/CFS-specific. Certainty Assessment:: 0.55 raw × 0.75 general-review weight = discounted 0.41

47 Torrelli-Diljohn et al. 2026 — Tryptophan Catabolism as a Distributed Signaling Network (COMPETING/INTEGRATIVE MECHANISM)

(Torrelli-Diljohn, Kulkarni, and Vitturi 2026)

Full Citation:: Torrelli-Diljohn A, Kulkarni B, Vitturi DA. Cell Signaling by Tryptophan Catabolism. Biochemistry. 2026;65(9):1366-1394. DOI:: 10.1021/acs.biochem.6c00179 PMID:: 42029070 Study Design:: Review Key Findings::

  • Tryptophan has three branches — kynurenine, serotonin, indole — and AhR is activated by metabolites from all three.
  • Downstream consequences depend on cellular environment and inflammatory context.
  • Frames kynurenine, indole/AhR, and serotonin as one distributed signaling network (also GPR35, NMDA, NAD+). Conclusion:: Provides the competing/integrative framing: the AhR axis is not separate from the already-covered kynurenine pathway but part of one distributed tryptophan-signaling network. Limitations:: Review; general biology; not ME/CFS-specific. Certainty Assessment:: 0.60 raw × 0.75 general-review weight = discounted 0.45

48 Morris et al. 2016 — TRYCATs and AhR Engagement in Neuro-Immune Disorders (TRYCAT REVIEW INCLUDING CFS)

(Morris et al. 2016)

Full Citation:: Morris G, Carvalho AF, Anderson G, Galecki P, Maes M. The Many Neuroprogressive Actions of Tryptophan Catabolites (TRYCATs) that may be Associated with the Pathophysiology of Neuro-Immune Disorders. Current Pharmaceutical Design. 2016;22(8):963-977. DOI:: 10.2174/1381612822666151215102420 PMID:: 26667000 Study Design:: Review Key Findings::

  • Chronic immune activation upregulates the IDO-driven tryptophan catabolite (TRYCAT) pathway, which becomes the predominant tryptophan-degradation route.
  • Neuroprotective kynurenic acid acts partly via alpha7 nicotinic acetylcholine and aryl hydrocarbon receptors.
  • Discusses the pathway in schizophrenia, Alzheimer’s disease, and chronic fatigue syndrome. Conclusion:: Bridges the already-integrated kynurenine pathway to AhR signaling in the ME/CFS context. Limitations:: Review; general neuro-immune (CFS discussed but not the study focus); older (2016). Certainty Assessment:: 0.55 raw × 0.75 general-review weight = discounted 0.41

49 Caccamo et al. 2013 — AHR Arg554Lys Variant in FM/CFS Cohort (AHR GENETIC VARIANT; PARTIAL NULL)

(Caccamo et al. 2013)

Full Citation:: Caccamo D, Cesareo E, Mariani S, Raskovic D, Ientile R, Curro M, Korkina L, De Luca C. Xenobiotic sensor- and metabolism-related gene variants in environmental sensitivity-related illnesses: a survey on the Italian population. Oxidative Medicine and Cellular Longevity. 2013;2013:831969. DOI:: 10.1155/2013/831969 PMID:: 23936614 Study Design:: Genetic association study; 80 FM/CFS patients, 156 MCS, 94 suspected MCS, 113 controls Key Findings::

  • Significantly higher frequencies of CYP2C9, CYP2C19, CYP2D6 metabolic variants in patients (genetic risk factor).
  • NULL on the sensor: AHR Arg554Lys variant distribution did NOT differ between SRI cases and controls, though it aided MCS/SMCS discrimination within haplotypes. Conclusion:: No simple genetic difference in the AHR sensor itself in CFS — pointing instead toward metabolite/ligand-level (rather than receptor-gene) differences, consistent with Esteban2026. Limitations:: Older (2013); heterogeneous SRI populations; AHR finding null for the case/control comparison; CFS+FM grouped together. Certainty Assessment:: 0.45 raw × 1.00 CFS cohort weight = discounted 0.45

50 Thirugnanam et al. 2026 — Dietary Indoles Restore AhR/IL-22 Intestinal Barrier (DIETARY INDOLES AHR-RORGT; ANIMAL MECHANISM)

(Thirugnanam et al. 2026)

Full Citation:: Thirugnanam S, Van Zandt AR, McNally AB, Hart VA, Berthelot I, Midkiff CC, Doyle-Meyers LA, Welsh DA, Blair RV, MacLean AG, Rout N. Dietary indoles influence the AHR-RORgt axis and mucosal immune homeostasis in ART-treated SIV infection. JCI Insight. 2026;11(10):e201258. DOI:: 10.1172/jci.insight.201258 PMID:: 41926722 Study Design:: Non-human-primate interventional study (SIV-infected rhesus macaques on ART); dietary indole supplementation for 1 month Key Findings::

  • Chronic SIV infection caused loss of IL-17/IL-22-producing gamma-delta T cells and ILC3s, reduced AHR/RORgt expression, and elevated gut-barrier markers (iFABP, zonulin, LBP).
  • One month of dietary indole supplementation restored colonic AHR+ IL-22-producing T cells and RORgt+ ILC3s and reduced barrier markers. Conclusion:: Directly demonstrates the gut-microbial-indole/AhR/IL-22-to-intestinal-barrier axis — central to the AhR hypothesis — in a chronic post-infectious model relevant to ME/CFS precedent. Limitations:: Animal model (SIV macaque, HIV not ME/CFS); interventional indole supplementation; cross-species translation gap. Certainty Assessment:: 0.50 raw × 0.50 animal weight = discounted 0.25 ## Kerrebijn et al. 2026 — Genetic Architecture of Fibromyalgia Across 2.5 Million Individuals (PRIMARY FIBROMYALGIA GENETICS)

(Kerrebijn et al. 2026)

Full Citation:: Kerrebijn I, Bjornsdottir G, Arbabi K, et al. The genetic architecture of fibromyalgia across 2.5 million individuals. Nature Medicine. 2026;32(8):3060-3070. DOI:: 10.1038/s41591-026-04492-6 PMID:: 42521817 Study Design:: Multi-ancestry GWAS meta-analysis; 11 cohorts, 54,629 cases / 2,509,126 controls (total 2,563,755) Key Findings::

  • 26 genome-wide-significant risk loci for fibromyalgia (ICD-10 M79.7).
  • Strongest association: HTT coding variant (inframe glutamic acid deletion, exon 58), OR=1.09, P=2.2e-12; distinct from Huntington’s disease repeat expansion.
  • Gene prioritization: HTT regulator GPR52, DCC, DRD2/NCAM1, MDGA2, CELF4 (all neural roles).
  • Heritability exclusively enriched in brain tissues and neural cell types; strongest = dentate gyrus neurons (P=1.3e-6) and enteric neurons; only significant lineage = neural.
  • Strong positive genetic correlations: rg > 0.7 with low back pain, PTSD, IBS, joint pain, hypermobility, myalgia, cervicobrachial syndrome.
  • Not primarily autoimmune: no significant MHC signal, no immune/glial heritability enrichment; modest autoimmune rg (stronger with seronegative RA and T2-low asthma).
  • No sex difference in genetic architecture (inter-sex rg = 1.03) despite 87.7% female cases.
  • Observed-scale heritability 10.4%; PRS AUC 0.59 (European); risk-quintile OR range 0.63-1.5. Conclusion:: Robust genetic evidence that fibromyalgia is a central nervous system (nociplastic) disorder with extensive shared genetic architecture across chronic pain, psychiatric, and somatic comorbidities — a biological framework directly relevant to the ME/CFS comorbidity relationship. Limitations:: Mostly European (90%); ICD-code-based case definition; single published meta-analysis not yet fully externally replicated locus-by-locus; cell-type enrichment resolution limited by overlapping gene expression; potential diagnostic misclassification of autoimmune overlaps. Certainty Assessment:: 0.85 raw × 0.80 fibromyalgia population weight = discounted 0.68

51 Bright et al. 2026 — Genetics of Fibromyalgia and Its Relationships to Psychiatric and Medical Traits (INDEPENDENT GWAS)

(Bright et al. 2026)

Full Citation:: Bright U, Beck S, Levey DF, et al. The genetics of fibromyalgia and its relationships to psychiatric and medical traits. Nature Communications. 2026;17(1):6248. DOI:: 10.1038/s41467-026-75256-6 PMID:: 42521668 Study Design:: Multi-ancestry GWAS (85,139 cases / 1,642,433 controls; Million Veteran Program-led) with MTAG, cross-ancestry, and GenomicSEM analyses Key Findings::

  • 10 loci in European, 1 in African, 12 cross-ancestry, 45 in European MTAG; most previously associated with pain, cognition, autoimmune response, or general health.
  • Moderate negative genetic correlation with physical activity; strong positive rg with chronic pain, PTSD, depression (rg >= 0.69).
  • GenomicSEM places fibromyalgia mostly as pain- and autoimmune-related trait; local genetic correlations point to neuronal mechanisms. Conclusion:: Independent GWAS confirming a neural/psychiatric-somatic genetic architecture for fibromyalgia and providing partial locus replication of the Kerrebijn 2026 meta-analysis. Limitations:: Primarily veteran/EHR-based population; no direct ME/CFS comparison; some overlap in cohort sources with other large biobank meta-analyses. Certainty Assessment:: 0.75 raw × 0.80 fibromyalgia population weight = discounted 0.60

52 Lin et al. 2026 — Shared Latent Genetic Liability Across Fibromyalgia and Psychiatric Traits (GenomicSEM)

(Lin et al. 2026)

Full Citation:: Lin L, Li Y, Ji F, et al. Shared latent genetic liability across fibromyalgia and psychiatric traits: Novel insights from genomic structural equation modeling. PLoS Genetics. 2026;22(1):e1012034. DOI:: 10.1371/journal.pgen.1012034 PMID:: 41576141 Study Design:: Phenotype-specific GWAS meta-analyses + GenomicSEM common-factor GWAS across fibromyalgia, insomnia, depression, anxiety; MR + FUMA enrichment Key Findings::

  • Strong pairwise genetic correlations (rg = 0.55-0.84) across the four phenotypes.
  • Common factor (mvFibroPsych) GWAS identified 49 lead SNPs across 43 loci (32 novel); 342 protein-coding genes prioritized.
  • Pathway enrichment in synaptic function; brain-wide MR links corpus callosum splenium FA inversely; proteome-wide MR prioritized CD40. Conclusion:: Evidence for a shared CNS/synaptic genetic factor underlying fibromyalgia-psychiatric comorbidity, consistent with a transdiagnostic central sensitization model. Limitations:: GWAS meta-analysis reuse of overlapping cohorts; MR assumptions; cross-sectional design; no direct ME/CFS analysis. Certainty Assessment:: 0.60 raw × 0.80 fibromyalgia population weight = discounted 0.48

53 Johnston et al. 2025 — Chronic Overlapping Pain Conditions and Nociplastic Pain (NOCIPLASTIC GENETICS)

(Johnston, Signer, and Huckins 2025)

Full Citation:: Johnston KJA, Signer R, Huckins LM. Chronic overlapping pain conditions and nociplastic pain. HGG Advances. 2025;6(1):100381. DOI:: 10.1016/j.xhgg.2024.100381 PMID:: 39497418 Study Design:: GenomicSEM common-factor GWAS + multivariate TWAS on six chronic overlapping pain conditions (COPCs); LDSC, gene-set, tissue-enrichment analyses Key Findings::

  • 24 independent SNPs and 127 unique genes associated with nociplastic pain.
  • Nociplastic pain is a polygenic trait with significant SNP heritability.
  • Significant genetic overlap with multisite chronic pain; smaller overlap with rheumatoid arthritis and neuropathic pain.
  • Tissue enrichment in cardiac/thyroid tissue; gene-set enrichment in cognitive, personality, metabolic traits. Conclusion:: Establishes nociplastic pain as a shared heritable factor underlying chronic overlapping pain conditions — directly supporting the central-sensitization genetic model relevant to fibromyalgia and ME/CFS comorbidity. Limitations:: Reuses existing COPC GWAS output; trait definitions heterogeneous across conditions; nociplastic pain as an inferred latent factor. Certainty Assessment:: 0.65 raw × 0.80 fibromyalgia population weight = discounted 0.52

54 Pan et al. 2025 — GWAS of Widespread Pain in the UK Biobank (WIDESPREAD PAIN)

(Pan et al. 2025)

Full Citation:: Pan Q, Cai T, Tao Y, et al. Genome-wide association study identifies novel genetic variants associated with widespread pain in the UK Biobank (N = 172,230). Molecular Pain. 2025;21:17448069251346603. DOI:: 10.1177/17448069251346603 PMID:: 40509746 Study Design:: GWAS of widespread pain (pain all over body) in UK Biobank (N=172,230) with sex-stratified analysis, genetic correlation, PheWAS, MR Key Findings::

  • Novel locus rs34691025 (P=1.76e-8) on chromosome 5q13.2 within ARHGEF28.
  • Sex-stratified analysis identified a novel female-specific locus in LRMDA (chromosome 10); biological sex difference in widespread pain genetics.
  • Significant genetic correlations with joint disorders and spondylosis. Conclusion:: Widespread pain — the hallmark of fibromyalgia — has its own genetic signal and sex-specific architecture, providing an independent pain-genetics data point. Limitations:: Self-reported single-item pain definition; moderate sample for widespread pain; female-specific locus not genome-wide significant. Certainty Assessment:: 0.55 raw × 0.80 fibromyalgia population weight = discounted 0.44

55 Rahman et al. 2021 — RNF123 Locus and Chronic Widespread Musculoskeletal Pain (CWP GWAS + REPLICATION)

(Rahman et al. 2021)

Full Citation:: Rahman MS, Winsvold BS, Chavez Chavez SO, et al. Genome-wide association study identifies RNF123 locus as associated with chronic widespread musculoskeletal pain. Annals of the Rheumatic Diseases. 2021;80(9):1227-1235. DOI:: 10.1136/annrheumdis-2020-219624 PMID:: 33926923 Study Design:: GWAS of chronic widespread musculoskeletal pain (6,914 cases / 242,929 controls) with replication in six independent European cohorts Key Findings::

  • Three loci: RNF123 (replicated, P=0.0002), ATP2C1 (suggestive), COMT (not replicated).
  • RNF123 and ATP2C1 both implicate calcium regulation.
  • Partial genetic correlations with depressive symptoms, BMI. Conclusion:: Confirms heritable genetic architecture of CWP (the fibromyalgia pain hallmark) and provides a replication warning: the commonly-studied COMT locus failed to replicate. Limitations:: CWP phenotype (not full fibromyalgia syndrome); replication limited to RNF123 locus; sex-stratified analyses limited. Certainty Assessment:: 0.70 raw × 0.80 fibromyalgia population weight = discounted 0.56

56 Clauw et al. 2024 — Is Fibromyalgia an Autoimmune Disorder? (AUTOIMMUNE DEBATE)

(Clauw et al. 2024)

Full Citation:: Clauw D, Sarzi-Puttini P, Pellegrino G, Shoenfeld Y. Is fibromyalgia an autoimmune disorder? Autoimmunity Reviews. 2024;23(1):103424. DOI:: 10.1016/j.autrev.2023.103424 PMID:: 37634681 Study Design:: Expert debate article (opposing viewpoints) on fibromyalgia autoimmunity Key Findings::

  • Presents the current hypothesis on fibromyalgia pathogenesis: genetic predisposition, stressful life events, inflammation, cognitive-emotional factors.
  • Concludes available data do not clearly establish a primary autoimmune pathogenesis. Conclusion:: Frames the autoimmune debate that Kerrebijn 2026 directly addresses with genetic evidence (no MHC signal, no immune heritability enrichment). Limitations:: Narrative/expert-opinion format, not a systematic review or primary study. Certainty Assessment:: 0.60 raw × 0.80 fibromyalgia population weight = discounted 0.48

57 Ablin 2025 — Fibromyalgia: A Genetic/Environmental Disease? (GENE-ENVIRONMENT REVIEW)

(Ablin 2025)

Full Citation:: Ablin JN. Fibromyalgia: are you a genetic/environmental disease? Pain Reports. 2025;10(3):e1256. DOI:: 10.1097/PR9.0000000000001256 PMID:: 40291383 Study Design:: Narrative review of fibromyalgia genetics, epigenetics, and environmental triggers Key Findings::

  • Reviews COMT and serotonin transporter gene polymorphisms and their correlation with fibromyalgia susceptibility.
  • Environmental factors (physical trauma, stress) potentiate syndrome severity.
  • Emerging microbiome and epigenetic-modification research provides new mechanistic insights. Conclusion:: Fibromyalgia reflects complex gene-environment interactions; provides the pre-GWAS candidate-gene context for the field. Limitations:: Narrative review, not systematic; candidate-gene associations largely not replicated in GWAS. Certainty Assessment:: 0.55 raw × 0.80 fibromyalgia population weight = discounted 0.44

58 Hu et al. 2025 — Brain Functional Networks and Fibromyalgia: Genetic Correlation and MR (CNS CAUSALITY)

(Hu et al. 2025)

Full Citation:: Hu Y, Yang G, Deng Z, et al. The casual associations between brain functional networks and fibromyalgia: A large-scale genetic correlation and Mendelian randomization study. Bioengineering. 2025;12(7):692. DOI:: 10.3390/bioengineering12070692 PMID:: 40722384 Study Design:: Two-sample Mendelian randomization + LDSC regression linking 191 rsfMRI brain-network traits to 8 fibromyalgia-related traits Key Findings::

  • Several brain-network traits genetically correlated with pain, insomnia, fibromyalgia, malaise/fatigue.
  • Some brain networks showed causal effects on fibromyalgia and its comorbidities. Conclusion:: Supports a causal CNS/brain-network contribution to fibromyalgia and comorbid fatigue, consistent with the central sensitization model. Limitations:: Moderate quality MR-based study; overlapping GWAS cohorts; brain-network trait inference; bioengineering-focused journal. Certainty Assessment:: 0.50 raw × 0.80 fibromyalgia population weight = discounted 0.40

59 D’Agnelli et al. 2019 — Fibromyalgia Genetics and Epigenetics for Diagnostic Biomarkers (PRE-GWAS CONTEXT)

(D’Agnelli et al. 2019)

Full Citation:: D’Agnelli S, Arendt-Nielsen L, Gerra MC, et al. Fibromyalgia: Genetics and epigenetics insights may provide the basis for the development of diagnostic biomarkers. Molecular Pain. 2019;15:1744806918819944. DOI:: 10.1177/1744806918819944 PMID:: 30486733 Study Design:: Review of fibromyalgia genetics and epigenetics (pre-2026 GWAS era) Key Findings::

  • Genetic factors possibly responsible for up to 50% of fibromyalgia disease susceptibility.
  • Candidate genes: SLC64A4, TRPV2, MYT1L, NRXN3.
  • Hypomethylated DNA pattern in stress-response, autonomic, and subcortical neuronal genes. Conclusion:: Pre-GWAS evidence supported a substantial genetic component and epigenetic involvement but produced no robust risk loci — the gap Kerrebijn 2026 resolved. Limitations:: Pre-GWAS review; candidate-gene findings largely not replicated; hypomethylation evidence preliminary. Certainty Assessment:: 0.50 raw × 0.80 fibromyalgia population weight = discounted 0.40

References

Ablin, J. N. 2025. “Fibromyalgia: Are You a Genetic/Environmental Disease?” Pain Reports 10 (3): e1256. https://doi.org/10.1097/PR9.0000000000001256.
Alshdefat, Ahmad, Ahmad Ayed, Ismael Aqtam, Omowunmi Ibitoye, Sherry Vincent, and Abdulaziz A Furqani. 2026. “Saffron and Pregnancy: Cultural Practices, Beliefs, and Safety Evidence: An Integrative Review.” Journal of Evidence-Based Integrative Medicine 31: 2515690X261455162. https://doi.org/10.1177/2515690X261455162.
Amadieu, Camille, Quentin Leyrolle, Marta Farneti, et al. 2025. “Effect of Saffron Extract Supplementation on Mood in Healthy Adults with Subclinical Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Trial.” American Journal of Clinical Nutrition 122 (6): 1625–35. https://doi.org/10.1016/j.ajcnut.2025.09.050.
Anacker, Christoph, and René Hen. 2017. “Adult Hippocampal Neurogenesis and Cognitive Flexibility – Linking Memory and Mood.” Nature Reviews Neuroscience 18 (6): 335–46. https://doi.org/10.1038/nrn.2017.45.
Barlattani, Tommaso, Giuseppe Celenza, Alessandro Cavatassi, Franco Minutillo, Valentina Socci, Carolina Pinci, Riccardo Santini, and Francesca Pacitti. 2025. “Neuropsychiatric Manifestations of COVID-19 Disease and Post COVID Syndrome: The Role of N-Acetylcysteine and Acetyl-l-Carnitine.” Current Neuropharmacology 23 (6): 686–704. https://doi.org/10.2174/011570159X343115241030094848.
Boldrini, Maura, Camille A. Fulmore, Alexandria N. Tartt, Laika R. Simeon, Iva Pavlova, Verica Poposka, Gorazd B. Rosoklija, et al. 2018. “Human Hippocampal Neurogenesis Persists Throughout Aging.” Cell Stem Cell 22 (4): 589–99. https://doi.org/10.1016/j.stem.2018.03.015.
Boldrini, Maura, Camille A. Fulmore, Alexandria N. Tartt, Laika R. Simeon, Iva Pavlova, Verica Poposka, Gorazd B. Rosoklija, et al. 2019. “Resilience Is Associated with Larger Dentate Gyrus, While Suicide Decedents with Major Depressive Disorder Have Fewer Granule Neurons.” Biological Psychiatry 85 (10): 850–62. https://doi.org/10.1016/j.biopsych.2018.12.022.
Boldrini, Maura, René Hen, Mark D. Underwood, Gorazd B. Rosoklija, Andrew J. Dwork, J. John Mann, and Victoria Arango. 2012. “Hippocampal Angiogenesis and Progenitor Cell Proliferation Are Increased with Antidepressant Use in Major Depression.” Biological Psychiatry 72 (7): 562–71. https://doi.org/10.1016/j.biopsych.2012.04.024.
Bright, U., S. Beck, D. F. Levey, J. D. Deak, J. M. Gaziano, M. B. Stein, and J. Gelernter. 2026. “The Genetics of Fibromyalgia and Its Relationships to Psychiatric and Medical Traits.” Nature Communications 17 (1): 6248. https://doi.org/10.1038/s41467-026-75256-6.
Buiting, Karin, Charles Williams, and Bernhard Horsthemke. 2016. “Angelman Syndrome – Insights into a Rare Neurogenetic Disorder.” Nature Reviews Neurology 12 (10): 584–93. https://doi.org/10.1038/nrneurol.2016.133.
Caccamo, Daniela, Eleonora Cesareo, Serena Mariani, Desanka Raskovic, Riccardo Ientile, Monica Curro, Liudmila Korkina, and Chiara De Luca. 2013. “Xenobiotic Sensor- and Metabolism-Related Gene Variants in Environmental Sensitivity-Related Illnesses: A Survey on the Italian Population.” Oxidative Medicine and Cellular Longevity 2013: 831969. https://doi.org/10.1155/2013/831969.
Căuș, Marius Nicolae, Mihaela Lupoae, and Carmen Lidia Chițescu. 2026. “Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data.” Pharmaceuticals (Basel) 19 (3): 399. https://doi.org/10.3390/ph19030399.
Cherneva, Dilyana I., Gabriela Kehayova, Simona Dimitrova, and Stela Dragomanova. 2025. “The Central Nervous System Modulatory Activities of N-Acetylcysteine: A Synthesis of Two Decades of Research.” Current Issues in Molecular Biology 47 (9): 710. https://doi.org/10.3390/cimb47090710.
Chojnacki, Marcin, Aleksandra Blonska, Aleksandra Kaczka, Jan Chojnacki, Ewa Walecka-Kapica, Natalia Romanowska, Karolina Przybylowska-Sygut, and Tomasz Poplawski. 2025. “Assessment of the Gut Microbiome in Patients with Coexisting Irritable Bowel Syndrome and Chronic Fatigue Syndrome.” Nutrients 17 (13): 2232. https://doi.org/10.3390/nu17132232.
Clauw, D., P. Sarzi-Puttini, G. Pellegrino, and Y. Shoenfeld. 2024. “Is Fibromyalgia an Autoimmune Disorder?” Autoimmunity Reviews 23 (1): 103424. https://doi.org/10.1016/j.autrev.2023.103424.
D’Agnelli, S., L. Arendt-Nielsen, M. C. Gerra, K. Zatorri, L. Boggiani, M. Baciarello, and E. Bignami. 2019. “Fibromyalgia: Genetics and Epigenetics Insights May Provide the Basis for the Development of Diagnostic Biomarkers.” Molecular Pain 15: 1744806918819944. https://doi.org/10.1177/1744806918819944.
Dastan, Farzaneh, Jamshid Salamzadeh, Jalal Heshmatnia, and Reza Mahmoudian. 2025. “Evaluating the Effects of Crocus sativus l. Herbal Product on Chronic Fatigue Syndrome in Patients with Chronic Obstructive Pulmonary Disease.” Iranian Journal of Pharmaceutical Research 24 (1): e165333. https://doi.org/10.5812/ijpr-165333.
De la Fuente Muñoz, Marina, Marta Román-Carmena, Sara Amor, Ángel L García-Villalón, Ana E Espinel, Daniel González-Hedström, and Miriam Granado García. 2023. “Effects of Supplementation with the Standardized Extract of Saffron (Affron) on the Kynurenine Pathway and the Synthesis of Melatonin in Rats.” Antioxidants (Basel) 12 (8): 1619. https://doi.org/10.3390/antiox12081619.
De Monte, Celeste, Simone Carradori, Paola Chimenti, Daniela Secci, Luisa Mannina, Federica Alcaro, Anél Petzer, Chunderika N’Da, et al. 2014. “New Insights into the Biological Properties of Crocus sativus l.: Chemical Modifications, Human Monoamine Oxidases Inhibition and Molecular Modeling.” European Journal of Medicinal Chemistry 82: 164–71. https://doi.org/10.1016/j.ejmech.2014.05.038.
Dimech, Lauren. 2026. “The Role of Saffron in the Treatment of Depression: A Literature Review.” Cureus 18 (3): e104594. https://doi.org/10.7759/cureus.104594.
Eriksson, Peter S., Ekaterina Perfilieva, Thomas Björk-Eriksson, Ann-Marie Alborn, Claes Nordborg, Daniel A. Peterson, and Fred H. Gage. 1998. “Neurogenesis in the Adult Human Hippocampus.” Nature Medicine 4 (11): 1313–17. https://doi.org/10.1038/3305.
Esteban, David J., Brynn Conrad, Autumn Cullinan, Sharon Luong, Jason Albaum, and Victoria Wilk. 2026. “Tryptophan Metabolism and Aryl-Hydrocarbon Receptor Agonists in the Gut Microbiome of People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” MicrobiologyOpen 15 (3): e70333. https://doi.org/10.1002/mbo3.70333.
Fernández-Castañeda, Anthony, Peiwen Lu, Anna C. Geraghty, Eric Song, Myoung-Hwa Lee, Jamie Wood, Michael R. O’Dea, et al. 2022. “Mild Respiratory COVID Can Cause Multi-Lineage Neural Cell and Myelin Dysregulation.” Cell 185 (14): 2452–68. https://doi.org/10.1016/j.cell.2022.06.008.
Fesharaki-Zadeh, Arman, Timothy Belliveau, Robert H. Pietrzak, and Amy Arnsten. 2025. “A Novel Multimodal Pharmacologic Approach Using Guanfacine, N-Acetylcysteine, and Donepezil in Severe TBI: A Case Series.” Frontiers in Rehabilitation Sciences 6: 1648002. https://doi.org/10.3389/fresc.2025.1648002.
Fesharaki-Zadeh, Arman, Naomi Lowe, and Amy F. T. Arnsten. 2023. “Clinical Experience with the \(\alpha\)2A-Adrenoceptor Agonist, Guanfacine, and N-Acetylcysteine for the Treatment of Cognitive Deficits in Long-COVID19.” Neuroimmunology Reports 3: 100154. https://doi.org/10.1016/j.nerep.2022.100154.
Gandy, Katelyn, Sarah Kim, Crystal Sharp, Lynn Gandy, Alejandro F. Schinder, Amar Sahay, and René Hen. 2017. “Pattern Separation: A Potential Marker of Impaired Hippocampal Adult Neurogenesis in Major Depressive Disorder.” Frontiers in Neuroscience 11: 571. https://doi.org/10.3389/fnins.2017.00571.
Hajhashemy, Zahra, Mohammad Bagherniya, and Omid Sadeghi. 2026. “The Effect of Saffron Supplementation on Indices of Oxidative Stress, Inflammation, Mental Health, and Quality of Life in Patients with Parkinson’s Disease.” Food & Function 17 (2): 889–901. https://doi.org/10.1039/d5fo01924a.
Horvath, Audrey E, Miriam Grozis, Peter R S Baker, et al. 2026. “Saffron Alters Microbial Amino Acid Metabolism and Neurotransmitter Production in a Defined Gut Consortium.” Food Science & Nutrition 14 (4): e71694. https://doi.org/10.1002/fsn3.71694.
Hu, Y., G. Yang, Z. Deng, S. Yang, Y. Li, W. Xiao, B. Lu, and X. Zhu. 2025. “The Casual Associations Between Brain Functional Networks and Fibromyalgia: A Large-Scale Genetic Correlation and Mendelian Randomization Study.” Bioengineering 12 (7): 692. https://doi.org/10.3390/bioengineering12070692.
Johnston, K. J. A., R. Signer, and L. M. Huckins. 2025. “Chronic Overlapping Pain Conditions and Nociplastic Pain.” HGG Advances 6 (1): 100381. https://doi.org/10.1016/j.xhgg.2024.100381.
Kerrebijn, Isabel, Gyda Bjornsdottir, Keon Arbabi, Lea Urpa, Hele Haapaniemi, Gudmar Thorleifsson, Lilja Stefansdottir, et al. 2026. “The Genetic Architecture of Fibromyalgia Across 2.5 Million Individuals.” Nature Medicine 32 (8): 3060–70. https://doi.org/10.1038/s41591-026-04492-6.
Khasnavis, Siddharth, Timothy Belliveau, Amy Arnsten, and Arman Fesharaki-Zadeh. 2024. “Combined Use of Guanfacine and N-Acetylcysteine for the Treatment of Cognitive Deficits After Traumatic Brain Injury.” Neurotrauma Reports 5 (1): 226–31. https://doi.org/10.1089/neur.2023.0124.
Kurmashev, Rustem. 2026. “UBE3A Dosage Imbalance as a Molecular Framework Linking Angelman Syndrome and Dup15q-Associated Autism Phenotypes.” American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. https://doi.org/10.1002/ajmg.b.70025.
Lang, Laura, Annelie Ditton, Andrei Stanescu, et al. 2025. “A Standardised Saffron Extract Improves Subjective and Objective Sleep Quality in Healthy Older Adults with Sleep Complaints: A Randomised, Placebo-Controlled Pilot Study.” Food & Function 16 (17): 6817–32. https://doi.org/10.1039/d5fo00917k.
Lin, L., Y. Li, F. Ji, J. Lin, M. Zhu, D. Liang, M. Cao, G. Fu, and Y. Fu. 2026. “Shared Latent Genetic Liability Across Fibromyalgia and Psychiatric Traits: Novel Insights from Genomic Structural Equation Modeling.” PLoS Genetics 22 (1): e1012034. https://doi.org/10.1371/journal.pgen.1012034.
Moghimi Dehkordi, Zohreh, Jamshid Salamzadeh, Maria Tavakoli-Ardakani, Atefeh Abedini, and Farzaneh Dastan. 2026. “Efficacy of a Saffron-Based (Crocus sativus l.) Herbal Supplement on Sleep Disturbances in Pulmonary Sarcoidosis Patients.” Iranian Journal of Pharmaceutical Research 25 (1): e169041. https://doi.org/10.5812/ijpr-169041.
Mohammadi, Sajad, Mostafa Naseri, Niloofar Faridi, Parisa Zareie, Leila Zare, Javad Mirnajafi-Zadeh, and S. Zahra Bathaie. 2023. “Saffron Carotenoids Reversed the UCMS-Induced Depression and Anxiety in Rats: Behavioral and Biochemical Parameters, and Inhibition of NMDA Receptor.” Phytomedicine 119: 154989. https://doi.org/10.1016/j.phymed.2023.154989.
Monchaux de Oliveira, Caroline, Adrien Vignault, Angèle Guille, et al. 2026. “Exploring the Neurofunctional Potential of Saffron Bioactives: From Mood-Related Behavioral Modulation to Brain Access of Its Compounds.” Food & Function 17 (6): 2800–2818. https://doi.org/10.1039/d5fo04830c.
Morris, Gerwyn, Andre F. Carvalho, George Anderson, Piotr Galecki, and Michael Maes. 2016. “The Many Neuroprogressive Actions of Tryptophan Catabolites (TRYCATs) That May Be Associated with the Pathophysiology of Neuro-Immune Disorders.” Current Pharmaceutical Design 22 (8): 963–77. https://doi.org/10.2174/1381612822666151215102420.
Okamoto, L. E., V. Urechie, S. Rigo, J. J. Abner, M. Giesecke, J. A. S. Muldowney, R. Furlan, et al. 2024. “Hyperadrenergic Postural Tachycardia Syndrome: Clinical Biomarkers and Response to Guanfacine.” Hypertension 81 (11): 2237–47. https://doi.org/10.1161/HYPERTENSIONAHA.124.23035.
Pan, Q., T. Cai, Y. Tao, L. Yang, R. Compte, M. K. Naeini, M. Haque, T. Dottorini, F. M. Williams, and W. Meng. 2025. “Genome-Wide Association Study Identifies Novel Genetic Variants Associated with Widespread Pain in the UK Biobank (n = 172,230).” Molecular Pain 21: 17448069251346603. https://doi.org/10.1177/17448069251346603.
Panov, Josif, Liron Simchi, Yaron Feuermann, and Hanoch Kaphzan. 2020. “Bioinformatics Analyses of the Transcriptome Reveal Ube3a-Dependent Effects on Mitochondrial-Related Pathways.” International Journal of Molecular Sciences 21 (11): 4156. https://doi.org/10.3390/ijms21114156.
Papadopoulos, Andrew S., and Anthony J. Cleare. 2012. “Hypothalamic-Pituitary-Adrenal Axis Dysfunction in Chronic Fatigue Syndrome.” Nature Reviews Endocrinology 8 (1): 22–32. https://doi.org/10.1038/nrendo.2011.153.
Peng, Madeleine S., Jialin Jiang, Lucia Polizzi, Tiancheng Shi, Rakshitha Ramkumar, Victor O. Anosike, Giulia Guasoni, et al. 2026. “Dysregulated Adult Hippocampal Neurogenesis in Major Depressive Disorders.” Nature Medicine 32. https://doi.org/10.1038/s41591-026-04571-8.
Qu, Shen, Jinjing Wang, Xiaoqian Guan, Caijun Song, and Xiaoyun Wang. 2024. “Sleep Disturbance in Angelman Syndrome Patients.” Orphanet Journal of Rare Diseases 19 (1): 146. https://doi.org/10.1186/s13023-024-03154-5.
Rahman, M. S., B. S. Winsvold, S. O. Chavez Chavez, S. Børte, Y. A. Tsepilov, S. Z. Sharapov, Y. S. Aulchenko, et al. 2021. “Genome-Wide Association Study Identifies RNF123 Locus as Associated with Chronic Widespread Musculoskeletal Pain.” Annals of the Rheumatic Diseases 80 (9): 1227–35. https://doi.org/10.1136/annrheumdis-2020-219624.
Rothhammer, Veit, and Francisco J. Quintana. 2019. “The Aryl Hydrocarbon Receptor: An Environmental Sensor Integrating Immune Responses in Health and Disease.” Nature Reviews Immunology 19 (3): 184–97. https://doi.org/10.1038/s41577-019-0125-8.
Simchi, Liron, Pratiksha K. Gupta, Yaron Feuermann, and Hanoch Kaphzan. 2023. “Elevated ROS Levels During the Early Development of Angelman Syndrome Alter the Apoptotic Capacity of the Developing Neural Precursor Cells.” Molecular Psychiatry 28 (6): 2382–97. https://doi.org/10.1038/s41380-023-02038-7.
Snyder, Jason S., Amelie Soumier, Michelle Brewer, James Pickel, and Heather A. Cameron. 2011. “Adult Hippocampal Neurogenesis Buffers Stress Responses and Depressive Behaviour.” Nature 476 (7361): 458–61. https://doi.org/10.1038/nature10287.
Sorrells, Shawn F., Mercedes F. Paredes, Arantxa Cebrian-Silla, Kadellyn Sandoval, Dashi Qi, Kevin W. Kelley, David James, et al. 2018. “Human Hippocampal Neurogenesis Drops Sharply in Children to Undetectable Levels in Adults.” Nature 555 (7696): 377–81. https://doi.org/10.1038/nature25975.
Sorrells, Shawn F., Mercedes F. Paredes, Zicong Zhang, Gina Kang, Olaya Pastor-Alonso, Sara Biagiotti, Chelsea E. Page, et al. 2021. “Positive Controls in Adults and Children Support That Very Few, If Any, New Neurons Are Born in the Adult Human Hippocampus.” Journal of Neuroscience 41 (12): 2554–65. https://doi.org/10.1523/JNEUROSCI.0676-20.2020.
Su, Hui, Wei Fan, Pinar E. Coskun, Jouni Vesa, Jeffrey A. Gold, Yong-hui Jiang, Prasanth Potluri, Douglas C. Wallace, Jane Gibson, and Virginia E. Kimonis. 2011. “Mitochondrial Dysfunction in CA1 Hippocampal Neurons of the UBE3A Deficient Mouse Model for Angelman Syndrome.” Neuroscience Letters 487 (2): 129–33. https://doi.org/10.1016/j.neulet.2009.06.079.
Tartt, Alexandria N., Madeline B. Mariani, René Hen, J. John Mann, and Maura Boldrini. 2022. “Dysregulation of Adult Hippocampal Neuroplasticity in Major Depression: Pathogenesis and Therapeutic Implications.” Molecular Psychiatry 27 (6): 2689–99. https://doi.org/10.1038/s41380-022-01520-y.
Thirugnanam, Siva, Alison R. Van Zandt, Alexandra B. McNally, Victoria A. Hart, Isabelle Berthelot, Cecily C. Midkiff, Lara A. Doyle-Meyers, et al. 2026. “Dietary Indoles Influence the AHR-RORgt Axis and Mucosal Immune Homeostasis in ART-Treated SIV Infection.” JCI Insight 11 (10): e201258. https://doi.org/10.1172/jci.insight.201258.
Tian, Chong, Shan Yang, Xinyao Zhang, and Hongyu Yan. 2026. “Ligand-Specific Duality of Aryl Hydrocarbon Receptor Signaling in Cognitive Health: From Environmental Neurotoxicity to Microbiome-Mediated Neuroprotection.” Frontiers in Neuroscience 20: 1823961. https://doi.org/10.3389/fnins.2026.1823961.
Tian, Huidi, Lei Wang, Elizabeth Aiken, Robert Jervine V. Ortega, Rachel Hardy, Lindsey Placek, Lina Kozhaya, Derya Unutmaz, Julia Oh, and Xudong Yao. 2024. “Fast Targeted Metabolomics for Analyzing Metabolic Diversity of Bacterial Indole Derivatives in ME/CFS Gut Microbiome.” bioRxiv (Preprint). https://doi.org/10.1101/2024.07.29.605643.
Torrelli-Diljohn, Alex, Bhargavi Kulkarni, and Dario A. Vitturi. 2026. “Cell Signaling by Tryptophan Catabolism.” Biochemistry 65 (9): 1366–94. https://doi.org/10.1021/acs.biochem.6c00179.
Videbech, Poul, and Barbara Ravnkilde. 2004. “Hippocampal Volume and Depression: A Meta-Analysis of MRI Studies.” American Journal of Psychiatry 161 (11): 1957–66. https://doi.org/10.1176/appi.ajp.161.11.1957.
Watanabe, Makoto, Takuya Goto, Riko Miyoshi, Shohei Nakakubo, Yumiko Hiramatsu, Ryosuke Nakajima, Akihiko Kondo, Kazuki Higashiyama, and Kazuhiro Yamakawa. 2026. “Region-Dependent Differences in Tonic Inhibition Underlie Epileptic Features in Angelman Syndrome Model Mice.” Epilepsia. https://doi.org/10.1002/epi.70307.
Wauquier, Fabien, Line Boutin-Wittrant, Line Pourtau, David Gaudout, Benjamin Moras, Adrien Vignault, Caroline Monchaux De Oliveira, Julien Gabaston, et al. 2022. “Circulating Human Serum Metabolites Derived from the Intake of a Saffron Extract Protect Human Neurons from Oxidative Stress-Induced Neurotoxicity.” Nutrients 14 (7): 1511. https://doi.org/10.3390/nu14071511.
Yan, Meiqiu, Menglin Shi, Chunwan Li, Bingqing Yu, Hengpu Zhou, Jie Su, Jingjing Yu, Guiyuan Lv, and Suhong Chen. 2026. “Effects of Dendrobium Officinale on Chronic Fatigue in Rats: Modulation of Tryptophan Metabolism.” Journal of Ethnopharmacology 365: 121527. https://doi.org/10.1016/j.jep.2026.121527.